Pharmaceuticals
Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...
2025-07-17 08:00
2312
SNB-101 Earns Government Backing as Promising Therapy for Small Cell Lung Cancer
SEONGNAM, South Korea, July 16, 2025 /PRNewswire/ -- In a strong endorsement of its cutting-edge drug delivery technology, SN BioScience announced that its anticancer candidate SNB-101 has been selected as a clinical-stage project under the 2025 Korea Drug Development Project, a government-initia...
2025-07-16 20:00
2009
WuXi Biologics Granted Highest Negligible-Risk ESG Rating from Morningstar Sustainalytics
* Best ESG rating tier of negligible-risk with a top 1% global ranking score * Industry and Regional ESG Top-Rated Company for five consecutive years * Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, July 16, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading ...
2025-07-16 18:00
1927
Senhwa Biosciences announces first patient dosed in NCI-sponsored pilot study of Pidnarulex (CX-5461) pharmacodynamics in patients with advanced solid tumors
TAIPEI and SAN DIEGO, July 15, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that its new drug Pidnarulex (CX-5461) has been selected by the U...
2025-07-16 10:32
2128
Akeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer
HONG KONG, July 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully enrolled in the registration Phase III clinical trial (AK112-312/HARMONi-GI6) of ivonescimab in first-line treatment for advanced metastati...
2025-07-16 09:47
2101
ArkBio's Ziresovir Included into Pediatric RSV Drug Priority List by WHO
SHANGHAI, July 16, 2025 /PRNewswire/ -- In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for Paediatric formulations (GAP-f), the World Health Organization (WHO) host network,ziresovir (10mg) has been included in ...
2025-07-16 09:00
2465
Ascletis Completes Dosing of All Participants in Its U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity
- The combination study, conducted in the U.S., is designed to evaluate the safety, tolerability and preliminary efficacy at Day 29 of a single-dose of ultra-long-acting subcutaneously administered ASC47 (half-life up to 40 days) in combination with four doses of semaglutide (0.5 mg, onc...
2025-07-15 07:00
2018
Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform
* Validates technological prowess of GAIA platform and intensifies global co-development effort, including the existing partnership with Lilly Catalyze360-ExploR&D * Funds to accelerate Alzheimer's and immune disease drug development, expanding GAIA-based pipeline SEOUL, South Korea, July 14,...
2025-07-14 15:38
1464
CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO
SHANGHAI, July 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces a favorable outcome in opposition proceedings before the European Patent Office (EPO) concerning its European patent EP34...
2025-07-14 08:00
1642
Bio Investments Group (BIG) and International Vaccine Institute (IVI) Forge Partnership to Accelerate Vaccine Self-Reliance in Africa and the Middle East
ZUG, Switzerland and SEOUL, July 11, 2025 /PRNewswire/ -- The Bio Investments Group AG (BIG), a leading global healthcare-technology transfer platform, and the International Vaccine Institute (IVI), an international organization dedicated to advancing vaccine discovery, development, and delivery,...
2025-07-11 23:08
3697
Earendil Labs announces initiation of a phase 1 study of a half-life extended novel anti-TL1A antibody
MIDDLETOWN, Del., July 10, 2025 /PRNewswire/ -- Earendil Labs, an AI-empowered biotechnology company, announced that it has completed cohort 1 dosing in a phase 1 trial for a novel anti-TL1A antibody (HXN-1001). The phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics,...
2025-07-10 19:00
1690
DKSH and Bayer Launch Strategic Partnership Across Multiple Markets in Southeast Asia
DKSH has signed a strategic business partnership with life science company Bayer, to provide comprehensive services for a portion of the Bayer Pharmaceuticals business in Singapore, Malaysia, Thailand and the Philippines. SINGAPORE, July 10, 2025 /PRNewswire/ -- DKSH Business Unit Healthcare, ...
2025-07-10 10:00
3209
Zhimeng Biopharma's Next-Generation KCNQ2/3 Potassium Channel Opener Receives Clinical Trial Approval for ALS Phase 2/3 Study
SHANGHAI, July 9, 2025 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma"), a clinical-stage biopharmaceutical company dedicated to innovative drug development for liver and central nervous system (CNS) diseases, today announced that its self-discovered next-generation KCNQ2/3 ...
2025-07-10 00:00
2375
LBB Specialties Expands Distribution Partnership with Clariant to Support Puerto Rico's Life Sciences Market
NORWALK, Conn., July 9, 2025 /PRNewswire/ -- LBB Specialties (LBBS), a leader in specialty chemicals and ingredient distribution in North America, is pleased to announce the expansion of its distribution partnership with Clariant, a global leader in the development and manufacturing of specialty c...
2025-07-09 23:00
2133
NYSE Content advisory: Pre-Market update + Trump announces 50% levy on copper imports
NEW YORK, July 9, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content advisory: Pre-Market update + Trump announces 50% le...
2025-07-09 20:55
3193
GenScript Biotech Earns EcoVadis Silver Medal, Ranking in Top 15% Globally for Sustainability
PISCATAWAY, N.J., July 9, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a leading global provider of life science research and manufacturing services, today announced that it has been awarded a Silver Medal by EcoVadis, a globally recognized business sustainability assessment plat...
2025-07-09 20:32
1988
IASO Bio Receives Orphan Drug Designation from the Ministry of Food and Drug Safety of South Korea for Equecabtagene Autoleucel
SHANGHAI, NANJING, China and SAN FRANCISCO, July 9, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced thatits self-developed an...
2025-07-09 20:18
2192
Gozellix Receives Permanent HCPCS Code
MELBOURNE, Australia, July 9, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that its next-generation PSMA[1] PET[2] imaging agent, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), has been granted a permanent Hea...
2025-07-09 12:41
3324
Watson-Marlow Fluid Technology Solutions focuses on BioClamp's sustainability benefits and new WMArchitect Interchangeable Parts service at INTERPHEX Tokyo 2025
TOKYO, July 9, 2025 /PRNewswire/ -- Visitors to the Watson-Marlow Fluid Technology Solutions booth W15-2 at INTERPHEX Tokyo 2025 (July 9-11 at Tokyo Big Sight, Japan) can learn more about the new WMArchitect Interchangeable Parts service as well as how recently advanced manufacturing of BioClamp ...
2025-07-09 11:30
2112
First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
SHANGHAI, July 8, 2025 /PRNewswire/ -- Duality Biotherapeutics' ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the first patient has been dosed in the Phase 1 portion of...
2025-07-09 11:14
2008
Week's Top Stories
Most Reposted
AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 302 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
Infobip strengthens leadership to drive growth and innovation
[Picked up by 282 media titles]
2026-01-16 11:00
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 280 media titles]
2026-01-20 15:40
Novo Holdings Invests in Surya Hospitals to Strengthen Access to High-Quality Women's and Children's Healthcare in India
[Picked up by 277 media titles]
2026-01-20 09:00
